Cited by 77Cancer-related Molecular PathwaysDNA Repair MechanismsHeat shock proteins research

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

Open access
Valentine, Jane M, Kumar, Sonia, Moumen, Abdeladim·2011·BMC Cancer

Abstract

Background: The mammalian DNA-damage response (DDR) has evolved to protect genome stability and maximize cell survival following DNA-damage. One of the key regulators of the DDR is p53, itself tightly regulated by MDM2. Following double-strand DNA breaks (DSBs), mediators including ATM are recruited to the site of DNA-damage. Subsequent phosphorylation of p53 by ATM and ATM-induced CHK2 results in p53 stabilization, ultimately intensifying transcription of p53-responsive genes involved in DNA repair, cell-cycle checkpoint control and apoptosis. Methods: In the current study, we investigated the stabilization and activation of p53 and associated DDR proteins in response to treatment of human colorectal cancer cells (HCT116 p53+/+) with the MDM2 antagonist, Nutlin-3. Results: Using immunoblotting, Nutlin-3 was observed to stabilize p53, and activate p53 target proteins. Unexpectedly, Nutlin-3 also mediated phosphorylation of p53 at key DNA-damage-specific serine residues (Ser15, 20 and 37). Furthermore, Nutlin-3 induced activation of CHK2 and ATM - proteins required for DNA-damage-dependent phosphorylation and activation of p53, and the phosphorylation of BRCA1 and H2AX - proteins known to be activated specifically in response to DNA damage. Indeed, using immunofluorescent labeling, Nutlin-3 was seen to induce formation of γH2AX foci, an early hallmark of the DDR. Moreover, Nutlin-3 induced phosphorylation of key DDR proteins, initiated cell cycle arrest and led to formation of γH2AX foci in cells lacking p53, whilst γH2AX foci were also noted in MDM2-deficient cells. Conclusion: To our knowledge, this is the first solid evidence showing a secondary role for Nutlin-3 as a DDR triggering agent, independent of p53 status, and unrelated to its role as an MDM2 antagonist.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2407-11-79

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 33 · Cited by 77

Authors
Valentine, J. M., Kumar, S., & Moumen, A.
Affiliations
St George's, University of London (GB)
Corresponding author
Moumen, Abdeladim
Venue
BMC Cancer
Published
2011-02-21
Volume
11
Issue
1
Pages
79-79
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2155786178
Cited by
77
References
33
Citations by year
2025: 2 · 2024: 5 · 2023: 7 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 8 · 2015: 6 · 2014: 10 · 2013: 6 · 2012: 11
FWCI
5.04
Type
journal article
Language
en
Open access
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Wellcome Trust
  • Karolinska Institutet
  • University of Texas MD Anderson Cancer Center
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
Nutlin-3, MDM2 inhibitors, DNA damage response, p53-independent signaling, p53 phosphorylation, ATM, Chk2, BRCA1 phosphorylation, H2AX phosphorylation, γH2AX foci, cell cycle arrest, colorectal cancer cells, genome stability
MeSH terms
Animals, Cells, Cultured, DNA Damage, Gene Expression Regulation, Humans, Imidazoles, Models, Biological, Phosphorylation, Piperazines, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, HCT116 Cells, Mice, Proto-Oncogene Proteins c-mdm2, Protein Stability, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review